SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?


To: sam who wrote (2757)5/14/1999 3:01:00 PM
From: AJAG  Respond to of 10280
 
Suppose that J & J decided that the drug (improved version of Hismanal) is not going to be better than either the improved version of Claritin or Allegra, both of which are SEPR products for the same problem, allergies. Do you think that this is bad news for SEPR?
I understand that the royalty deal for SEPR on the improved version of Claritin is a good one. Either way, the allergy sufferers will probably be taking a SEPR drug, unless someone comes up with a cure for allergies.